The Viborg Vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: study protocol

Nikolaj Grøndal, Rikke Søgaard, Eskild W Henneberg, Jes S Lindholt, Nikolaj Grøndal, Rikke Søgaard, Eskild W Henneberg, Jes S Lindholt

Abstract

Background: Screening for abdominal aortic aneurysm (AAA) of men aged 65-74 years reduces the AAA-related mortality and is generally considered cost effective. Despite of this only a few national health care services have implemented permanent programs. Around 10% of men in this group have peripheral arterial disease (PAD) defined by an ankle brachial systolic blood pressure index (ABI) below 0.9 resulting in an increased mortality-rate of 25-30%. In addition well-documented health benefits may be achieved through primary prophylaxis by initiating systematic cholesterol-lowering, smoking cessation, low-dose acetylsalicylic acid (aspirins), exercise, a healthy diet and blood-pressure control altogether reducing the increased risks for cardiovascular disease by at least 20-25%. The benefits of combining screening for AAA and PAD seem evident; yet they remain to be established. The objective of this study is to assess the efficacy and the cost-effectiveness of a combined screening program for AAA, PAD and hypertension.

Methods: The Viborg Vascular (VIVA) screening trial is a randomized, clinically controlled study designed to evaluate the benefits of vascular screening and modern vascular prophylaxis in a population of 50,000 men aged 65-74 years. Enrolment started October 2008 and is expected to stop in October 2010. The primary outcome is all-cause mortality. The secondary outcomes are cardiovascular mortality, AAA-related mortality, hospital services related to cardiovascular conditions, prevalence of AAA, PAD and potentially undiagnosed hypertension, health-related quality of life and cost effectiveness. Data analysis by intention to treat.

Results: Major follow-up will be performed at 3, 5 and 10 years and final study result after 15 years.

Trial registration: ClinicalTrials.gov NCT00662480.

Figures

Figure 1
Figure 1
Expected flow-chart concerning vascular screening (VIVA) for peripheral arterial disease, abdominal aortic aneurysm and hypertension.

References

    1. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ. 2005;11:750. doi: 10.1136/bmj.38369.620162.82.
    1. Ehlers L, Overvad K, Sorensen J, Christensen S, Bech M, Kjolby M. Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm. BMJ. 2009;11:b2243. doi: 10.1136/bmj.b2243.
    1. The Danish health economic modelling study on AAA screening is flawed.
    1. Thompson SG, Ashton HA, Gao L, Scott RA. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ. 2009;11:b2307. doi: 10.1136/bmj.b2307.
    1. Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. Eur J Vasc Endovasc Surg. 2000;11:636–642. doi: 10.1053/ejvs.2000.1066.
    1. Cornuz J, Sidoti PC, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health. 2004;11:343–349. doi: 10.1093/eurpub/14.4.343.
    1. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, ngles-Cano E, Michel JB. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol. 2002;11:1701–1710.
    1. Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P, Meilhac O, Guillin MC, Michel JB. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006;11(3):1022–30. doi: 10.2353/ajpath.2006.050868.
    1. Lindholt JS, Sorensen HT, Michel JB, Thomsen HF, Henneberg EW. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg. 2008;11:329–334. doi: 10.1177/1538574408315205.
    1. Schouten O, van Laanen JHH, Boersma E, Vidakovic R, Feringa HHH, Dunkelgrün M, Bax JJ, Koning J, van Urk H, Poldermans D. Statins are Associated with a Reduced Infrarenal Abdominal Aortic Aneurysm Growth. Eur J Vasc Endovasc Surg. 2006;11:21–26. doi: 10.1016/j.ejvs.2005.12.024.
    1. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006;11:659–665. doi: 10.1016/S0140-6736(06)69250-7.
    1. Lindholt JS. Relatively high pulmonary and cardiovascular mortality rates in screening-detected aneurysmal patients without previous hospital admissions. Eur J Vasc Endovasc Surg. 2007;11:94–99. doi: 10.1016/j.ejvs.2006.06.007.
    1. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa. 2004;11:183–189. doi: 10.1024/0301-1526.33.4.183.
    1. McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med. 2006;11(Suppl 4):S2–S7. doi: 10.3949/ccjm.73.Suppl_4.S2.
    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group. Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur J Vasc Endovasc Surg. 2007;11(Suppl 1):S1–75. doi: 10.1016/j.ejvs.2006.09.024.
    1. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts); Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Reimer Scholte op W, Weissberg P, Wood D, Yarnell J, Zamorano JL. Other experts who contributed to parts of the guidelines; Walma E, Fitzgerald T, Cooney MT, Dudina A. European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;11:2375–2414. doi: 10.1093/eurheartj/ehm316.
    1. Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health. 2009;11:467–474. doi: 10.1177/1403494809105286.
    1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
    1. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–430. doi: 10.1002/hec.678.
    1. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;11:S68–S80. doi: 10.1177/0272989X9801800209.
    1. Moussa ID, Jaff MR, Mehran R, Gray W, Dangas G, Lazic Z, Moses JW. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter Cardiovasc Interv. 2009;11:719–724. doi: 10.1002/ccd.21969.
    1. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg E. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;11:1185–1191. doi: 10.1016/j.jvs.2007.02.004.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever